Navegando por Palavras-chave "Health Care Costs"

Agora exibindo 1 - 3 de 3
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Aplicações diretas para aquisição de medicamentos no Sistema Único de Saúde
    (Faculdade de Saúde Pública da Universidade de São Paulo, 2011-10-01) Vieira, Fabiola Sulpino [UNIFESP]; Zucchi, Paola [UNIFESP]; Ministério da Saúde Secretaria Executiva Departamento de Economia da Saúde e Desenvolvimento; Universidade Federal de São Paulo (UNIFESP)
    OBJECTIVE: To analyze resource allocation for pharmaceutical procurement by federative entities in the Brazilian Unified Health System. METHODS: The amounts allocated to purchase pharmaceuticals during 2009 in two information systems were analyzed: Siga Brasil (Follow Brazil) for national data and Sistema de Informações sobre Orçamentos Públicos em Saúde (Information System on Public Health Budgets) for states, the Federal District and municipalities data. Per capita spending and the mean and median spending were calculated by municipalities, according to region and population size. The Spearman correlation coefficient was calculated for some variables. The statistical analysis included tests of normality and multiple comparisons for differences between groups. RESULTS: In 2009 the total amount spent by the three spheres of government for purchase of medicines was approximately R$ 8.9 billion. States and the Federal District were the main players, accounting for 47.1% of the total amount spent in the health system. Some states had per capita spending well above the mean (R$ 22.00 per resident/year) and the median (R$ 17.00 per resident/year). There were differences in municipal spending by region. The mean per capita expenditure of municipalities with less than 5,000 residents was 3.9 times that of municipalities with over 500,000 residents. Municipalities with less than 10,000 residents had higher per capita spending than other municipalities. CONCLUSIONS: Economic aspects such as the scale of procurement and bargaining power may explain differences in per capita spending between federal entities, especially among municipalities. The study indicates inefficiencies in the use of financial resources to procure medicines in the Brazilian Unified Health System.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo
    (Faculdade de Saúde Pública da Universidade de São Paulo, 2011-02-01) Daltio, Claudiane Salles [UNIFESP]; Mari, Jair de Jesus [UNIFESP]; Ferraz, Marcos Bosi [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    OBJECTIVE: To assess direct medical costs associated with schizophrenia relapses in mental health services. METHODS: The study was conducted in three health facilities in the city of São Paulo: a public state hospital; a Brazilian National Health System (SUS)-contracted hospital; and a community mental health center. Medical records of 90 patients with schizophrenia who received care in 2006 were reviewed. Information on inpatient expenditures was collected and used for cost estimates. RESULTS: Mean direct medical cost of schizophrenia relapses per patient was US$ 4,083.50 (R$ 8,167.58) in the public state hospital; US$ 2,302.76 (R$ 4,605.46) in the community mental health center; and US$ 1,198.50 (R$ 2,397.74) in the SUS-affiliated hospital. The main component was daily inpatient room rates (87% - 98%). Medication costs varied depending on the use of typical or atypical antipsychotic drugs. Atypical antipsychotic drugs were more often used in the community mental health center. CONCLUSIONS: Costs associated with schizophrenia relapses support investments in antipsychotic drugs and strategies to reduce disease relapse and the need for mental health inpatient services. Treating patients in a community mental health center was associated with medium costs and added the benefit of not depriving these patients from family life.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Oncoplastic approach in the conservative treatment of breast cancer: analysis of costs
    (Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia, 2012-05-01) Lima, Débora Eleotério De; Veiga Filho, Joel [UNIFESP]; Ribeiro, Leda Marques; Morais, Thiago Bezerra De; Rocha, Luiz Roberto Martins [UNIFESP]; Juliano, Yara; Veiga, Daniela Francescato [UNIFESP]; Ferreira, Lydia Masako [UNIFESP]; UNIVÁS Plastic Surgery Division; UNIVÁS Mastology Division; UNIVÁS Hospital das Clínicas Samuel Libânio Plastic Surgery Division; UNIVÁS School of Administration; UNIVÁS Bioestatistics Division; Universidade Federal de São Paulo (UNIFESP)
    PURPOSE: To analyze the direct costs of conservative surgical treatment of breast cancer, performed in a university hospital, to the Brazilian National Health Care Public System (SUS), checking the impact of the oncoplastic approach on these costs. METHODS: One hundred thirty eight breast cancer patients who had undergone conservative treatment with oncoplastic approach (n=36) or not (control group, n=102), in the period from 2005 to 2010, were enrolled. Sociodemographic and clinical data were recorded. The direct costs of the surgical procedure were obtained and analyzed. RESULTS: Groups did not differ in regard to age (p=0.963), and patients in oncoplastic group had a longer time of hospital stay (p=0.000). The median direct cost for the oncoplastic group was R$461.00 and for the control group was R$229.00 (p=0.000). CONCLUSION: The oncoplastic approach has generated higher direct costs in conservative surgical treatment of breast cancer to SUS.